Design and synthesis of 6,6-fused heterocyclic amides as raf kinase inhibitors

Abstract Compounds belonging to several scaffolds—quinazolines, quinolines and quinoxalines—were designed and synthesized as Raf kinase inhibitors. Scaffolds were assessed for in vitro Braf V600E inhibition, and overall kinase selectivity. Pharmacokinetic parameters for one of the scaffolds were also determined.